Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
7 studies found for:    Boeckh
Show Display Options
Rank Status Study
1 Recruiting Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure
Conditions: Acute Lung Injury;   Acute Respiratory Distress Syndrome;   Respiratory Failure
Interventions: Drug: IV Ganciclovir;   Drug: Placebo
2 Completed Ribavirin Compared With Standard Care in Treating Patients With Respiratory Syncytial Virus Following Stem Cell Transplantation
Condition: Infection
Intervention: Drug: ribavirin
3 Completed Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation
Condition: Infection
Interventions: Drug: ganciclovir;   Drug: valganciclovir
4 Completed
Has Results
TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients
Condition: Influenza
Interventions: Drug: TCAD;   Drug: Zanamivir or Oseltamivir;   Other: Open label treatment with TCAD
5 Completed Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant
Condition: VZV Infection After Bone Marrow Transplantation
Intervention: Drug: Acyclovir
6 Completed Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation
Condition: Cancer
Interventions: Biological: palivizumab;   Drug: ribavirin
7 Recruiting A Study of the Safety and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients
Conditions: CMV;   Adenoviruses (AdV);   Epstein-Barr (EBV);   Human Herpes Virus Type 6 (HHV6);   BK Virus (BKV)
Intervention: Drug: Brincidofovir (CMX001)

Indicates status has not been verified in more than two years